RETRACTED ARTICLE: Menière’s disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline—an observational study

Strupp, Michael; Kraus, L; Schautzer, Franz; Rujescu, Dan

doi:10.1007/s00415-018-8809-8

Cited by 9 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since it is used in daily life, the ecological validity might be improved compared to many currently available questionnaires which are administered once a week at most. These aspects will likely be very valuable when investigating the effect of therapies for vestibular disorders, especially in cases of fluctuating symptoms like in Menière's disease [40,53]. In the future, it could open doors to ecological momentary interventions, which take place in real time and in real world [54].…”

Section: Discussionmentioning

confidence: 99%

Introducing the DizzyQuest: an app-based diary for vestibular disorders

et al. 2020

View full text Add to dashboard Cite

Background Most questionnaires currently used for assessing symptomatology of vestibular disorders are retrospective, inducing recall bias and lowering ecological validity. An app-based diary, administered multiple times in daily life, could increase the accuracy and ecological validity of symptom measurement. The objective of this study was to introduce a new experience sampling method (ESM) based vestibular diary app (DizzyQuest), evaluate response rates, and to provide examples of DizzyQuest outcome measures which can be used in future research. Methods Sixty-three patients diagnosed with a vestibular disorder were included. The DizzyQuest consisted of four questionnaires. The morning- and evening-questionnaires were administered once each day, the within-day-questionnaire 10 times a day using a semi-random time schedule, and the attack questionnaire could be completed after the occurrence of a vertigo or dizziness attack. Data were collected for 4 weeks. Response rates and loss-to-follow-up were determined. Reported symptoms in the within-day-questionnaire were compared within and between patients and subgroups of patients with different vestibular disorders. Results Fifty-one patients completed the study period. Average response rates were significantly higher than the desired response rate of > 50% (p < 0.001). The attack-questionnaire was used 159 times. A variety of neuro-otological symptoms and different disease profiles were demonstrated between patients and subgroups of patients with different vestibular disorders. Conclusion The DizzyQuest is able to capture vestibular symptoms within their psychosocial context in daily life, with little recall bias and high ecological validity. The DizzyQuest reached the desired response rates and showed different disease profiles between subgroups of patients with different vestibular disorders. This is the first time ESM was used to assess daily symptoms and quality of life in vestibular disorders, showing that it might be a useful tool in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Introducing the DizzyQuest: an app-based diary for vestibular disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 18 The enzyme monoaminoxidase B (MAO-B) converts betahistine into aminoethylpyridine, hydroxyethylpyridine and mainly 2-pyridylacetic acid (2-PAA). 23 The effect of 2-PAA, however, differs in comparison with unmetabolized betahistine on cochlear microcirculation. In a study by Bertlich et al, 16 2-PAA proved non-effective in increasing cochlear blood flow compared to its precursor.…”

Section: Introductionmentioning

confidence: 99%

Low Dose Betahistine in Combination With Selegiline Increases Cochlear Blood Flow in Guinea Pigs

Kloos

Bertlich

Spiegel

et al. 2022

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

Objective: Betahistine is frequently used in the pharmacotherapy for Menière’s Disease (MD). Little is known about its mode of action and prescribed dosages vary. While betahistine had an increasing effect on cochlear microcirculation in earlier studies, low dose betahistine of 0.01 mg/kg bw or less was not able to effect this. Selegiline inhibits monoaminooxidase B and therefore potentially the breakdown of betahistine. The goal of this study was to examine whether the addition of selegiline to low dose betahistine leads to increased cochlear blood flow. Methods: Twelve Dunkin-Hartley guinea pigs were anesthetized, the cochlea was exposed and a window opened to the stria vascularis. Blood plasma was visualized by injecting fluoresceinisothiocyanate-dextrane and vessel diameter and erythrocyte velocity were evaluated over 20 minutes. One group received low dose betahistine (0.01 mg/kg bw) and selegiline (1 mg/kg bw) i.v. while the other group received only selegiline (1 mg/kg bw) and saline (0.9% NaCl) as placebo i.v. Results: Cochlear microcirculation increased significantly ( P < .001) in guinea pigs treated with low dose betahistine combined with selegiline by up to 58.3 ± 38.7% above baseline over a period of up to 11 minutes. In one guinea pig, the increase was 104.6%. Treatment with Selegiline alone did not affect microcirculation significantly. Conclusions: Low dose betahistine increased cochlear microcirculation significantly when combined with selegiline. This should be investigated in further studies regarding dose-effect relation in comparison to betahistine alone. Side effects, in particular regarding circulation, should be considered carefully in view of the clinical applicability of a combination therapy in patients with MD.

show abstract

“…The authors have retracted this article [1] because it erroneously gives the impression that the results presented were based on a clinical trial, when in fact the patients treated in this observational study underwent so-called "individuelle Heilversuche" (individual patient treatment). "Individuelle Heilversuche" is a type of medical treatment that deviates from the established medical standard.…”

mentioning

confidence: 99%